Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
NCT00093028
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
315
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
CC-5013 (Revlimid™)
DRUG:
bortezomib
Sponsor
University of Arkansas